Business Description
Azora Therapeutics is a California-based drug development company focused on creating new medicines for people living with immune-related and inflammatory conditions, particularly those affecting the skin and digestive system. Its lead program, AT177, is designed to treat ulcerative colitis by acting directly in the colon, reducing the risk of side effects that come with drugs absorbed throughout the body. Founded in 2017 and headquartered in Encino, the company was previously called Meya Pharmaceuticals before rebranding in 2019.
